Tablet Formulation of 2-((3-(Chloromethyl)benzoyl)oxy)benzoic Acid by Linear and Quadratic Models.
Journal
ACS omega
ISSN: 2470-1343
Titre abrégé: ACS Omega
Pays: United States
ID NLM: 101691658
Informations de publication
Date de publication:
27 Sep 2022
27 Sep 2022
Historique:
received:
26
05
2022
accepted:
17
08
2022
entrez:
3
10
2022
pubmed:
4
10
2022
medline:
4
10
2022
Statut:
epublish
Résumé
This research determines the effect of sodium lauryl sulfate (SLS) as a surfactant, croscarmellose sodium (CS) as a disintegrating agent, and SLS-CS combinations on 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid (3CH The tablets are manufactured through direct compression according to the simplex lattice design. The optimal SLS and CS concentration was determined in vitro using linear and quadratic models to achieve better tablet disintegration and dissolution. The same linear and quadratic coefficient profiles of SLS and CS indicate that the combined coefficient of SLS-CS with a quadratic model can be used to predict the effect of the SLS-CS combination. Based on the linear model coefficients, SLS and CS increase the value of flow time (9.35; 7.65), Carr index (26.17; 21.17), hardness (9.84; 7.44), friability (0.38; 0.31), disintegrating time (5.74; 2.62), and drug release (84.28; 58.65). The quadratic model coefficient shows that SLS-CS combinations increase flow time (0.60), Carr index (2.00), hardness (1.00), and disintegrating time (1.04). Meanwhile, they decrease friability (-0.02) and drug release (-9.10). SLS, CS, and SLS-CS combinations affect the quality of tablet mass and tablets. The optimum tablet formula was 3CH
Identifiants
pubmed: 36188286
doi: 10.1021/acsomega.2c03147
pmc: PMC9520729
doi:
Types de publication
Journal Article
Langues
eng
Pagination
34045-34053Informations de copyright
© 2022 The Authors. Published by American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Comput Math Methods Med. 2019 Aug 14;2019:4091464
pubmed: 31485257
Int J Pharm. 2018 Apr 5;540(1-2):185-193
pubmed: 29421301
Pharmaceutics. 2013 Oct 11;5(4):508-24
pubmed: 24300560
Prostaglandins Other Lipid Mediat. 2019 Dec;145:106364
pubmed: 31356853
J Drug Deliv. 2014;2014:827035
pubmed: 25328710
AAPS PharmSciTech. 2014 Oct;15(5):1093-104
pubmed: 24848762
Pharmaceutics. 2019 Mar 21;11(3):
pubmed: 30901930
Int J Pharm. 2014 Oct 1;473(1-2):64-72
pubmed: 24993785
Pharmazie. 2011 Sep;66(9):677-83
pubmed: 22026123
J Pharm Biomed Anal. 2005 Apr 1;37(4):679-85
pubmed: 15797788
PLoS One. 2020 Feb 12;15(2):e0223201
pubmed: 32050259
Saudi Pharm J. 2017 Jul;25(5):770-779
pubmed: 28725150
J Pharm Sci. 2019 Jan;108(1):516-524
pubmed: 30389564
AAPS PharmSciTech. 2013 Sep;14(3):950-8
pubmed: 23761262
AAPS J. 2010 Sep;12(3):263-71
pubmed: 20373062
Turk J Pharm Sci. 2017 Apr;14(1):40-48
pubmed: 32454593
Prostaglandins Other Lipid Mediat. 2021 Jun;154:106549
pubmed: 33831580